Companion diagnostics market seen topping $22.6 billion by 2030

By AI, Created 2:45 PM UTC, May 22, 2026, /AGP/ – The Business Research Company projects the global companion diagnostics market will reach $22.6 billion by 2030, driven by precision medicine, targeted therapies and rising chronic disease burden. North America and the U.S. are expected to remain the biggest regional and country markets, respectively.

Why it matters: - Companion diagnostics are becoming a bigger part of personalized medicine by helping match patients to targeted treatments. - The market is projected to represent about 10% of the in-vitro diagnostics market by 2030, showing how closely diagnostics are tied to drug selection. - The category is also expected to account for nearly 2% of the broader medical equipment market by 2030.

What happened: - The Business Research Company published a forecast saying the global companion diagnostics market will reach $22.6 billion by 2030. - The report puts the market at a 21% compound annual growth rate leading up to 2030. - The company also forecasts the market will surpass $23 billion in 2030. - A free sample of the report is available online.

The details: - North America is forecast to be the largest regional market in 2030 at $8.2 billion. - North America’s companion diagnostics market is expected to rise from $3.3 billion in 2025 at a 20% CAGR. - The USA is projected to be the largest country market in 2030 at $7.5 billion. - The U.S. market is expected to grow from $3.0 billion in 2025 at a 20% CAGR. - Assays, kits and reagents are expected to be the biggest product and service segment, reaching $15 billion and representing 66% of the market in 2030. - The market is also segmented by technology into polymerase chain reaction, next-generation sequencing, in situ hybridization and immunohistochemistry. - The market is segmented by indication into lung cancer, breast cancer, colorectal cancer, leukemia and melanoma. - The market is segmented by end user into pharmaceutical and biopharmaceutical companies, reference laboratories and contract research organizations. - A detailed market report is also available.

Between the lines: - Precision medicine is a central growth driver because companion diagnostics help identify which patients are most likely to benefit from a therapy. - Targeted therapies and biologics are pushing drug developers toward parallel development of tests and treatments. - Rising cancer, cardiovascular and rare genetic disease burden is increasing demand for earlier and more accurate diagnosis. - The report estimates precision medicine adoption will add about 2.5% annual growth, targeted therapies and biologics about 2.2%, and chronic and genetic disease prevalence about 2.0%. - The strongest opportunities are expected in assays, kits and reagents, plus software and services, which together could add more than $14 billion by 2030. - The assays, kits and reagents segment is projected to grow by $9 billion from 2025 to 2030. - The software and services segment is projected to grow by $5 billion over the same period.

What’s next: - Demand is likely to keep rising as more therapies require biomarker-based patient selection. - Diagnostic and pharmaceutical companies are expected to continue co-developing tests alongside new drugs. - Laboratories may see more pressure to scale standardized testing with higher sensitivity, specificity and faster data interpretation.

The bottom line: - Companion diagnostics are shifting from a niche testing category to a core part of targeted treatment planning, with growth tied to how quickly precision medicine expands.